




ASX: CUV  
Nasdaq International Designation: CLVLY  
XETRA-DAX: UR9

## New drug to repair damaged skin and reduce skin cancer risk

*Can a drug really repair DNA? One Australian company is asking just that*

Media Release

Melbourne, Australia, 10 September 2020



**Figure 1:** CLINUVEL's DNA Repair Program aims to confirm that intervention with SCENESSE® causes elimination of DNA damage (photoproducts) and regeneration of DNA.

The diagram shows that SCENESSE® has been proven to protect skin from light (photoprotection) and shown to repair DNA damage. Since photoprotection and regeneration are necessary to reduce the risk of skin cancer, the role of SCENESSE® is obvious. In the diagram, "P" stands for probability.

A leading Australian pharmaceutical company is testing whether a treatment can help repair skin damage caused by exposure to ultraviolet (UV) and visible light. If successful the drug, SCENESSE® (afamelanotide 16mg), would slow the rates of photoaging and reduce the risk of skin cancer.

SCENESSE® has shown positive results in preventing and repairing DNA damage caused by the sun, which leads to premature ageing through collagen and elastin reduction in skin while UV exposure increases the risk of development of skin cancers. The Australian company, CLINUVEL, is running clinical trials to confirm the ability of SCENESSE® to repair the DNA in skin cells, focusing initially on patients who are at a 10,000-fold risk of skin cancer due to a rare disease known as xeroderma pigmentosum (XP). XP is the most extreme form of intolerance to sunlight when patients develop skin cancers at a high rate.

"Light and UV radiation are constantly attacking our skin cells, causing damage to our DNA," Dr Pilar Bilbao, CLINUVEL's Clinical Operations Manager said. "The body can repair most of this damage, but over time or when we have too much UV exposure, our natural defence mechanisms fall short. When this happens the damage accumulates, leading to visible photoaging and possibly skin cancer in fair skinned people.

"Much research has shown that agents like SCENESSE® have the ability to aid the DNA repair process. We are testing this for the first time in individuals with XP – patients who are unable to repair skin damage on their own – and will rapidly expand our research as results allow.

“We look forward to confirming what we have seen in earlier clinical research: we have the technology and knowhow to repair DNA damage in humans, thus potentially reducing the risk of skin cancer,” Dr Bilbao said.

Skin damage from UV and visible light – known as photodamage – is most commonly the result of exposure to sunlight, but can also result from overexposure to artificial light and radiation, including from phones and computer screens. When light penetrates the skin, it damages the DNA within skin cells.

CLINUVEL is developing a range of products based on its very targeted research with SCENESSE®, including topical formulations of its proprietary drugs and over-the-counter products, and has recently opened a new Research and Development Centre in Singapore to accelerate this work. First results from the use of SCENESSE® in XP patients are expected in 2021. The scientific data from SCENESSE® has led to further products for general use.

**- END -**

<sup>1</sup> SCENESSE® (afamelanotide 16mg) is approved in the European Union as an orphan medicinal product for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). SCENESSE® is approved in the USA to increase “pain-free” light exposure in adult EPP patients with a history of phototoxicity. Information on the product can be found on CLINUVEL’s website at [www.clinuvel.com](http://www.clinuvel.com).

Note to editors: a technical release has been lodged with the ASX. CLINUVEL CEO Dr Philippe Wolgen is available for interview through Monsoon Communications.

#### **About CLINUVEL PHARMACEUTICALS LIMITED**

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic, skin, and systemic disorders. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL’s research and development initially has led to innovative treatments for patient populations with a clinical need for photoprotection and repigmentation. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 and the US Food and Drug Administration in 2019 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at <http://www.epp.care>. CLINUVEL is advancing its portfolio of melanocortins, among which is PRÉNUMBRA® for the treatment of several critical disorders. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information please go to <http://www.clinuvel.com>.

SCENESSE® and PRÉNUMBRA® are registered trademarks of CLINUVEL PHARMACEUTICALS LTD.

#### **Media enquiries**

Monsoon Communications  
Mr Rudi Michelson, 61 411 402 737, [rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)  
Level 39, 55 Collins Street, Melbourne, Victoria, Australia 3000

#### **Head of Investor Relations**

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

#### **Investor enquiries**

<https://www.clinuvel.com/investors/contact-us>

#### **Forward-Looking Statements**

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL’s management. Please see the complete disclaimer on forward-looking statements at [www.clinuvel.com](http://www.clinuvel.com).

[www.clinuvel.com](http://www.clinuvel.com)

Level 11 T +61 3 9660 4900  
535 Bourke Street F +61 3 9660 4999  
Melbourne  
Victoria, Australia, 3000